Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Ellison Zelski, Stephanie J ^a   Alarid, Elaine T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 10; DEATH RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; G PROTEIN COUPLED RECEPTOR; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; MYC PROTEIN; TRANSCRIPTION FACTOR SIN3A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; REPRESSOR PROTEIN; SIN3A TRANSCRIPTION FACTOR; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL LINE; CELL TYPE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; BREAST TUMOR; CELL CYCLE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

RUMEX;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 77957116043     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-263     Document Type: Article

References (61)

1. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
3. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
4. Macgregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998, 50:151-196.
5. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006, 38:1289-1297. 10.1038/ng1901, 17013392.
6. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003, 144:4562-4574. 10.1210/en.2003-0567, 12959972.
7. Kininis M, Chen BS, Diehl AG, Isaacs GD, Zhang T, Siepel AC, Clark AG, Kraus WL. Genomic analyses of transcription factor binding, histone acetylation, and gene expression reveal mechanistically distinct classes of estrogen-regulated promoters. Mol Cell Biol 2007, 27:5090-5104. 10.1128/MCB.00083-07, 1951957, 17515612.
8. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, Yeo A, George J, Kuznetsov VA, Lee YK, Charn TH, Palanisamy N, Miller LD, Cheung E, Katzenellenbogen BS, Ruan Y, Bourque G, Wei CL, Liu ET. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 2007, 3:e87. 10.1371/journal.pgen.0030087, 1885282,1885282, 17542648.
9. Ellison-Zelski SJ, Solodin NM, Alarid ET. Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter. Mol Cell Biol 2009, 29:4949-4958. 10.1128/MCB.00383-09, 2738295, 19620290.
10. Cowley SM, Iritani BM, Mendrysa SM, Xu T, Cheng PF, Yada J, Liggitt HD, Eisenman RN. The mSin3A chromatin-modifying complex is essential for embryogenesis and T-cell development. Mol Cell Biol 2005, 25:6990-7004. 10.1128/MCB.25.16.6990-7004.2005, 1190252, 16055712.
11. Dannenberg JH, David G, Zhong S, van der Torre J, Wong WH, Depinho RA. mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival. Genes Dev 2005, 19:1581-1595. 10.1101/gad.1286905, 1172064, 15998811.
12. Suzuki H, Ouchida M, Yamamoto H, Yano M, Toyooka S, Aoe M, Shimizu N, Date H, Shimizu K. Decreased expression of the SIN3A gene, a candidate tumor suppressor located at the prevalent allelic loss region 15q23 in non-small cell lung cancer. Lung Cancer 2008, 59:24-31. 10.1016/j.lungcan.2007.08.002, 17854949.
13. Nasmyth K, Stillman D, Kipling D. Both positive and negative regulators of HO transcription are required for mother-cell-specific mating-type switching in yeast. Cell 1987, 48:579-587. 10.1016/0092-8674(87)90236-4, 3028642.
14. Sternberg PW, Stern MJ, Clark I, Herskowitz I. Activation of the yeast HO gene by release from multiple negative controls. Cell 1987, 48:567-577. 10.1016/0092-8674(87)90235-2, 3545494.
15. Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 1997, 89:341-347. 10.1016/S0092-8674(00)80214-7, 9150133.
16. Zhang Y, Iratni R, Erdjument-Bromage H, Tempst P, Reinberg D. Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. Cell 1997, 89:357-364. 10.1016/S0092-8674(00)80216-0, 9150135.
17. Silverstein RA, Ekwall K. Sin3: a flexible regulator of global gene expression and genome stability. Curr Genet 2005, 47:1-17. 10.1007/s00294-004-0541-5, 15565322.
18. Ayer DE, Lawrence QA, Eisenman RN. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 1995, 80:767-776. 10.1016/0092-8674(95)90355-0, 7889570.
19. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999, 13:2490-2501. 10.1101/gad.13.19.2490, 317076, 10521394.
20. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386-389. 10.1038/30764, 9620804.
21. Roopra A, Sharling L, Wood IC, Briggs T, Bachfischer U, Paquette AJ, Buckley NJ. Transcriptional repression by neuron-restrictive silencer factor is mediated via the Sin3-histone deacetylase complex. Mol Cell Biol 2000, 20:2147-2157. 10.1128/MCB.20.6.2147-2157.2000, 110831, 10688661.
22. Lutz M, Burke LJ, Barreto G, Goeman F, Greb H, Arnold R, Schultheiss H, Brehm A, Kouzarides T, Lobanenkov V, Renkawitz R. Transcriptional repression by the insulator protein CTCF involves histone deacetylases. Nucleic Acids Res 2000, 28:1707-1713. 10.1093/nar/28.8.1707, 102824, 10734189.
23. Brown MA, Sims RJ, Gottlieb PD, Tucker PW. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol Cancer 2006, 5:26. 10.1186/1476-4598-5-26, 1524980, 16805913.
24. Burgio G, La Rocca G, Sala A, Arancio W, Di Gesu D, Collesano M, Sperling AS, Armstrong JA, van Heeringen SJ, Logie C, Tamkun JW, Corona DF. Genetic identification of a network of factors that functionally interact with the nucleosome remodeling ATPase ISWI. PLoS Genet 2008, 4:e1000089. 10.1371/journal.pgen.1000089, 2390755, 18535655.
25. Wysocka J, Myers MP, Laherty CD, Eisenman RN, Herr W. Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are tethered together selectively by the cell-proliferation factor HCF-1. Genes Dev 2003, 17:896-911. 10.1101/gad.252103, 196026, 12670868.
26. Yang L, Mei Q, Zielinska-Kwiatkowska A, Matsui Y, Blackburn ML, Benedetti D, Krumm AA, Taborsky GJ, Chansky HA. An ERG (ets-related gene)-associated histone methyltransferase interacts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B. Biochem J 2003, 369:651-657. 10.1042/BJ20020854, 1223118, 12398767.
27. Yang X, Zhang F, Kudlow JE. Recruitment of O-GlcNAc transferase to promoters by corepressor mSin3A: coupling protein O-GlcNAcylation to transcriptional repression. Cell 2002, 110:69-80. 10.1016/S0092-8674(02)00810-3, 12150998.
28. Sif S, Saurin AJ, Imbalzano AN, Kingston RE. Purification and characterization of mSin3A-containing Brg1 and hBrm chromatin remodeling complexes. Genes Dev 2001, 15:603-618. 10.1101/gad.872801, 312641, 11238380.
29. Prall OW, Rogan EM, Sutherland RL. Estrogen regulation of cell cycle progression in breast cancer cells. J Steroid Biochem Mol Biol 1998, 65:169-174. 10.1016/S0960-0760(98)00021-1, 9699870.
30. Saceda M, Lippman ME, Chambon P, Lindsey RL, Ponglikitmongkol M, Puente M, Martin MB. Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol Endocrinol 1988, 2:1157-1162. 10.1210/mend-2-12-1157, 3216858.
31. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998, 94:695-698. 10.1016/S0092-8674(00)81728-6, 9753316.
32. Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003, 113:207-219. 10.1016/S0092-8674(03)00234-4, 12705869.
33. Zhang H, Stephens LC, Kumar R. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res 2006, 12:1479-1486. 10.1158/1078-0432.CCR-05-1519, 16533771.
34. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006, 12:1168-1174. 10.1158/1078-0432.CCR-05-1533, 16489070.
35. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003, 100:11606-11611. 10.1073/pnas.1933744100, 208805, 14500907.
36. Gompel A, Somai S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, Forgez P, Mimoun M, Rostene W. Hormonal regulation of apoptosis in breast cells and tissues. Steroids 2000, 65:593-598. 10.1016/S0039-128X(00)00172-0, 11108864.
37. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009, 625:131-142. 10.1016/j.ejphar.2009.10.011, 19836388.
38. Wong ST. Emerging treatment combinations: integrating therapy into clinical practice. Am J Health Syst Pharm 2009, 66:S9-14. 10.2146/ajhp090439, 19923318.
39. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Gandara DR, Aparicio A, Somlo G, Wong C. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 2008, 14:7138-7142. 10.1158/1078-0432.CCR-08-0122, 18981013.
40. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009, 15:2488-2496. 10.1158/1078-0432.CCR-08-1930, 19318486.
41. Baltus GA, Kowalski MP, Tutter AV, Kadam S. A positive regulatory role for the mSin3A-HDAC complex in pluripotency through Nanog and Sox2. J Biol Chem 2009, 284:6998-7006. 10.1074/jbc.M807670200, 2652339, 19139101.
42. Vermeulen M, Walter W, Le Guezennec X, Kim J, Edayathumangalam RS, Lasonder E, Luger K, Roeder RG, Logie C, Berger SL, Stunnenberg HG. A feed-forward repression mechanism anchors the Sin3/histone deacetylase and N-CoR/SMRT corepressors on chromatin. Mol Cell Biol 2006, 26:5226-5236. 10.1128/MCB.00440-06, 1592717, 16809761.
43. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998, 281:1305-1308. 10.1126/science.281.5381.1305, 9721089.
44. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276:111-113. 10.1126/science.276.5309.111, 9082980.
45. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271:12687-12690. 10.1074/jbc.271.22.12687, 8663110.
46. MacFarlane M. TRAIL-induced signaling and apoptosis. Toxicol Lett 2003, 139:89-97. 10.1016/S0378-4274(02)00422-8, 12628743.
47. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995, 81:495-504. 10.1016/0092-8674(95)90070-5, 7758105.
48. Sax JK, El-Deiry WS. Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. J Biol Chem 2003, 278:36435-36444. 10.1074/jbc.M303191200, 12788948.
49. Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 2001, 98:13884-13888. 10.1073/pnas.241358198, 61136, 11717445.
50. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997, 90:405-413. 10.1016/S0092-8674(00)80501-2, 9267021.
51. Ledgerwood EC, Morison IM. Targeting the apoptosome for cancer therapy. Clin Cancer Res 2009, 15:420-424. 10.1158/1078-0432.CCR-08-1172, 19147745.
52. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489. 10.1016/S0092-8674(00)80434-1, 9390557.
53. Fei P, Wang W, Kim S, Wang S, Burns TF, Sax JK, Buzzai M, Dicker DT, McKenna WG, Bernhard EJ, El-Deiry WS. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 2004, 6:597-609. 10.1016/j.ccr.2004.10.012, 15607964.
54. Chinnadurai G, Vijayalingam S, Gibson SB. BNIP3 subfamily BH3-only proteins: mitochondrial stress sensors in normal and pathological functions. Oncogene 2009, 27:S114-S127.
55. Pungaliya P, Kulkarni D, Park HJ, Marshall H, Zheng H, Lackland H, Saleem A, Rubin EH. TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins. J Proteome Res 2007, 6:3918-3923. 10.1021/pr0703674, 17803295.
56. Farias EF, Petrie K, Leibovitch B, Murtagh J, Chornet MB, Schenk T, Zelent A, Waxman S. Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells. Proc Natl Acad Sci USA 2010, 107:11811-11816. 10.1073/pnas.1006737107, 20547842.
57. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci USA 1996, 93:4948-4952. 10.1073/pnas.93.10.4948, 39385, 8643509.
58. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980, 46:2884-2888. 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U, 7448733.
59. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992, 10:1284-1291.
60. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
61. Valley CC, Solodin NM, Powers GL, Ellison SJ, Alarid ET. Temporal variation in estrogen receptor-alpha protein turnover in the presence of estrogen. J Mol Endocrinol 2008, 40:23-34. 10.1677/JME-07-0067, 18096994.